It would be worth analyzing the sensitivity to these drugs in other cancer types presenting ATRX mutations, such as hepatocellular carcinoma, pancreatic neuroendocrine tumors, and neuroblastomas, and in cells with different genetic backgrounds. This evidence concerns the gene ATRX and hepatocellular carcinoma.